Rhinomed Limited engages in the research, development, and commercialization of consumer and medical devices worldwide. It identifies, acquires, and commercializes nasal stent delivery technologies. The company's product portfolio includes Turbine for enhanced breathing in sports; Mute, an anti-snoring device; and Pronto for nasal congestion and sleep disturbance issues. It also engages in developing applications for the delivery of medical cannabis and conditions, including anxiety, pain, allergies, nausea, anxiety, and coughs and colds; and nasal swab to test the presence of upper respiratory tract diseases, including influenza, and coronavirus strains. The company was formerly known as Consegna Group Limited and changed its name to Rhinomed Limited in November 2013. Rhinomed Limited was incorporated in 2004 and is based in Richmond, Australia.
Read More
